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OBJECTIVE— To test the association of regional fat depots with circulating adiponectin and
resistin concentrations and to assess the potential mediating effect of adipokines on associations
between abdominal fat depots and cardiometabolic risk factors.
RESEARCH DESIGN AND METHODS— Participants from the Framingham Heart
Study offspring cohort (n 916, 55% women; mean age 59 years) free of cardiovascular disease
underwent computed tomography measurement of visceral adipose tissue (VAT), subcutaneous
adipose tissue (SAT), pericardial fat, and intrathoracic fat volumes and assays of circulating
adiponectin and resistin.
RESULTS— VAT, SAT, pericardial fat, and intrathoracic fat were negatively correlated with
adiponectin (r0.19 to0.34, P 0.001 [women]; r0.15 to0.26, P 0.01 [men]
except SAT) and positively correlated with resistin (r  0.16–0.21, P  0.001 [women]; r 
0.11–0.14, P  0.05 [men] except VAT). VAT increased the multivariable model R2 for adi-
ponectin from 2–4% to 10–13% and for resistin from 3–4% to 3–6%. Adjustment for adipo-
kines did not fully attenuate associations between VAT, SAT, and cardiometabolic risk factors.
CONCLUSIONS— Adiponectin and resistin are correlated with fat depots cross-sectionally,
but none of the adipokines can serve as surrogates for the fat depots. Relations between VAT,
SAT, and cardiometabolic risk factors were not fully explained by adiponectin or resistin
concentrations.
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The risk of cardiometabolic diseasesincreases with fat accumulation inectopic depots (1–5). Visceral adi-
pose tissue (VAT) is more associated with an
increased risk of developing diabetes, hy-
pertension, dyslipidemia, and metabolic
syndrome compared with subcutaneous
adipose tissue (SAT) (1,2). Pericardial fat
and intrathoracic fat may also confer addi-
tional metabolic risk (4,5). The increased
metabolic risk associated with ectopic fat
depots may be due to their associations with
adiponectin (6,7). However, prior studies
(6–8) have been limited in size or age dis-
tribution and used only one or two com-
puted tomography (CT) slices to measure
abdominal fat area, which might lead to in-
accuracy in measurement of actual regional
fat deposits. In addition, it is not clear
whether indexes of regional adiposity con-
tribute to interindividual variation in sys-
temic adipokine concentrations beyond
anthropometric measures such as BMI and
waist circumference (6–8). In this study,
we investigated the cross-sectional associa-
tions of regional fat depots and circulating
levels of adiponectin and resistin and as-
sessed whether these adipokines mediate
the association of abdominal fat depots with
cardiometabolic risk factors.
RESEARCH DESIGN AND
METHODS— Participants were se-
lected from the Framingham Heart Study
multidetector CT substudy of the com-
munity-based Framingham Heart Study
offspring cohort; inclusion criteria have
been described previously (1). Beginning
in 1971, the offspring study enrolled the
offspring and spouses of the offspring
whose parents were in the original cohort
of the Framingham Heart Study. A subset
of the offspring cohort had measurements
of adipokine concentrations at their sev-
enth examination cycle between 1998
and 2001.
Of 1,418 participants in the off-
spring cohort of the multidetector CT
study, 1,342 participants had interpret-
able CT measurements of visceral,
subcutaneous, pericardial, and in-
trathoracic fat volume between 2002
and 2005. Plasma adiponectin and re-
sistin concentrations were available in
1,060 of 1,342 participants. After ex-
cluding participants with clinically
prevalent cardiovascular disease (CVD),
prior coronary artery bypass graft, and
an incomplete covariate profile, the fi-
nal sample size was 916 (501 women
and 415 men). The institutional review
boards of Boston University Medical
Center and Massachusetts General Hos-
pital approved this study. Written in-
formed consent was obtained from all
participants.
Adipokine measurements
Circulating concentrations of adiponectin
and resistin were measured by enzyme-
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linked immunosorbent assay (R&D Sys-
tems, Minneapolis, MN) in plasma
collected after a 8-h fast and frozen at
80°C. Intra-assay coefficients of varia-
tion were 5.8% for adiponectin and 9.0%
for resistin. Single, random plasma adi-
ponectin and resistin concentrations have
been shown to be stable over a 1-year pe-
riod (9).
Volumetric adipose tissue imaging
An 8-slice multidetector CT (LightSpeed
Ultra; General Electric, Milwaukee, WI)
was used to image the abdomen and tho-
rax. While lying in a supine position, par-
ticipants had an average of 25 contiguous
5-mm-thick cross-sectional images (120
kVp; 40 mA; gantry rotation time, 500
ms; table feed, 3:1) of the abdomen and
48 contiguous 2.5-mm-thick cross-
sectional images of the heart (120 kVp;
400 mA; temporal resolution, 330 ms).
The abdominal images spanned 125 mm
above the level of S1. The specific proto-
cols used to obtain images of the abdo-
men and thorax have been described
elsewhere (5,10).
Abdominal and thoracic adipose
tissue measurements
Visceral, subcutaneous, pericardial, and
thoracic fat volumes were measured
(Aquarius 3D Workstation; TeraRecon,
San Mateo, CA) using an image display
window width of 195 to 45
Hounsfield units (HU) and window cen-
ter of 120 HU. The readers manually
traced the abdominal muscular wall sep-
arating the visceral and subcutaneous de-
pots and outlined the pericardium to
distinguish pericardial from thoracic fat.
Pericardial fat volume included all adi-
pose tissue visualized within the pericar-
dial sac. Total thoracic fat volume
consisted of adipose tissue from the right
pulmonary artery to the diaphragm and
from the chest wall to the descending
aorta, including fat within the pericardial
sac. Interreader reproducibility was excel-
lent for visceral, subcutaneous, pericardial,
and thoracic fat volume measurements
(1,10). Intrathoracic fat was derived after
subtracting pericardial fat from total tho-
racic fat to identify two mutually exclusive
fat compartments.
Risk factor and covariate assessment
Cardiometabolic risk factors and other
covariates were assessed at the contempo-
raneous examination. BMI was measured
as weight (in kilograms) divided by the
square of height (in meters). Waist cir-
cumference was measured at the level of
the umbilicus. Tobacco and alcohol use
were self-reported through physician-
administered questions. Participants were
classified as current smokers if they
smoked on average at least one cigarette
per day in the previous year. Women who
drank 7 alcoholic drinks per week and
men who consumed 14 alcoholic
drinks per week were considered alcohol
users. The physical activity index was
based on the average number of hours per
day spent sleeping and doing sedentary,
slight, moderate, and heavy activity.
Women were considered postmeno-
pausal if they had not had any menstrual
periods for at least 1 year.
Hypertension was diagnosed as a sys-
tolic blood pressure 140 mmHg, a dia-
stolic blood pressure 90 mmHg, or
treatment with antihypertensive agents.
Fasting morning plasma samples were
collected to measure fasting plasma glu-
cose, total cholesterol, HDL cholesterol,
and triglycerides. Diabetes was defined as
a fasting plasma glucose126 mg/dl (7
mmol/l) or treatment with insulin or a hy-
poglycemic medication. Metabolic syn-
drome was defined based on modified
Adult Treatment Plan III criteria.
Statistical analysis
Adiponectin, VAT, SAT, pericardial fat,
and intrathoracic fat volumes were ap-
proximately normally distributed. Resis-
tin was logarithmically transformed to
normalize the distribution. All analyses
were a priori performed specific to sex
due to strong sex interactions we had pre-
viously observed with SAT and VAT (1).
Sex-specific and age-adjusted Pearson cor-
relation coefficients were calculated to de-
termine the correlation between each fat
compartment, adiponectin, and log resistin.
Sex-specific multivariable linear re-
gression was used to evaluate the associ-
ations of adiponectin and log resistin
(dependent variables; separate models for
each) with fat depots (independent vari-
ables), after adjustment for age, smoking,
alcohol use, menopausal status (women
only), and hormone replacement therapy
(women only). VAT, SAT, pericardial fat,
and intrathoracic fat were standardized to
a means  SD of 0  1; the covariate-
adjusted average change in adiponectin
and log resistin per SD of adipose tissue
volume was estimated. Using this ap-
proach, the multivariable regression re-
sults for each fat compartment could be
more directly compared. The multivari-
able models for VAT, pericardial fat, and
intrathoracic fat were then additionally
adjusted for BMI and waist circumference
in order to assess whether relations were
maintained after adjusting for measures of
generalized adiposity. As secondary anal-
yses, multivariable models for VAT, SAT,
pericardial fat, and intrathoracic fat were
also additionally adjusted for physical ac-
tivity and education status.
Multivariable linear and logistic re-
gressions were used to relate VAT and
SAT (independent variables) to cardiom-
etabolic risk factors (dependent vari-
ables). Models for systolic blood pressure,
fasting plasma glucose, log triglycerides,
HDL cholesterol, and metabolic syn-
drome were evaluated (separate model for
each risk factor). Age, smoking, alcohol
use, menopausal status (women only),
hormone replacement therapy (women
only), and treatment of hypertension,
dyslipidemia, and diabetes were entered
as covariates in each of the models. Each
multivariable model was also adjusted for
either adiponectin or log resistin (separate
models for each adjustment) to assess the
extent of attenuation of the association of
VAT and SAT with each cardiometabolic
risk factor upon adjustment for these adi-
pokines. All analyses were performed us-
ing SAS version 9.1. A two-tailed value of
P  0.05 was considered statistically
significant.
RESULTS
Study sample characteristics
Overall, 916 participants were available
for analysis. The mean age was 59 years
(Table 1), and slightly more than one-
quarter were obese. The majority of
women were postmenopausal.
Age-adjusted correlations between
fat depots and adipokines
VAT, SAT, pericardial fat, and intratho-
racic fat were negatively correlated with
adiponectin (r  0.19 to 0.34, P 
0.001 [women]; r  0.15 to 0.26,
P  0.01 [men] except SAT) and posi-
tively correlated with resistin (r 
0.16 – 0.21, P  0.001 [women]; r 
0.11– 0.14, P  0.05 [men] except
VAT) (Table 2).
Multivariable-adjusted regressions
with fat depots and adiponectin
In women, adiponectin concentration
was 2.1  0.3 g/ml lower per SD in-
crease of VAT, 1.2 0.3 g/ml lower per
SD increase of SAT, 1.2  0.3 g/ml
lower per SD increase of pericardial fat,
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and 1.2  0.3 g/ml lower per SD in-
crease of intrathoracic fat (P  0.001) in
multivariable-adjusted models (Table 3).
The regression coefficients for adiponec-
tin concentration were larger per SD of
VAT than per SD of SAT (P  0.001). In
men, the multivariable-adjusted effect
sizes of VAT, SAT, pericardial fat, and in-
trathoracic fat on adiponectin concentra-
tion were weaker but still significant in
nearly all cases (Table 3). A sex-by-VAT
interaction was observed for adiponectin
(P 0.001), as well as a sex-by-SAT (P
0.001) and sex–by–pericardial fat inter-
action (P  0.03).
In women, VAT remained associated
with adiponectin after additional adjust-
ment for BMI and waist circumference
(P  0.001); pericardial fat and in-
trathoracic fat did not remain associated
with adiponectin (P  0.15 [pericardial
fat], P  0.5 [intrathoracic fat]). In con-
trast, among men, VAT, pericardial fat,
and intrathoracic fat were associated with
adiponectin after further adjustment for
BMI and waist circumference (all P 
0.02).
Covariates (age, sex, smoking, alco-
hol use, menopausal status, and hormone
replacement therapy) explained 2% of the
circulating variability in adiponectin con-
centration in women and 4% in men;
adding VAT to this model increased the
model R2 to 13% in women and 10% in
men (Table 3). Multivariable-adjusted
models for SAT, pericardial fat, and in-
trathoracic fat accounted for a smaller
portion of the variation in adiponectin
concentration (R2 range 4–8%).
Multivariable-adjusted regressions
with fat depots and resistin
VAT, SAT, pericardial fat, and intratho-
racic fat were associated with resistin. Sex
interactions were not observed (all P 
0.1). In women, additional adjustment
for BMI and waist circumference attenu-
ated associations between VAT, pericar-
dial fat, intrathoracic fat, and resistin (all
P  0.2). Results were similar for men,
except intrathoracic fat remained associ-
ated with resistin after additional adjust-
ment for BMI and waist circumference
(P  0.02). None of the multivariable-
adjusted models explained a substantial
portion of the variability in resistin con-
centration (R2 range 3–6%).
Secondary analyses
When physical activity and education
status were included as additional co-
variates, relations between adipose tis-
sue volumes, adiponectin, and resistin
were not materially different (data not
shown).
Multivariable-adjusted regressions
with VAT, SAT, and cardiometabolic
risk factors additionally adjusted for
adipokines
VAT was associated with all cardiometa-
bolic risk factors in both sexes as previously
reported (1), except for systolic blood
pressure in men (online appendix Tables
1Aand1B[availableathttp://care.diabetes
journals.org/cgi/content/full/dc08-1733/
DC1]).
In women, we observed some attenu-
ation of the effect size of VAT on log trig-
lycerides and HDL cholesterol after
Table 1—Clinical characteristics of 916 study participants
Women Men
n 501 415
Age (years) 59  9 59  9
BMI (kg/m2) 27.8  5.3 28.8  4.4
Waist circumference (inches) 38  6 41  4
Obesity (%) 28.1 29.4
Triglycerides (mg/dl) 109 (77–163) 116 (77–174)
HDL cholesterol (mg/dl) 61  16 46  12
Total cholesterol (mg/dl) 206  36 195  33
Dyslipidemia treatment (%) 14.4 15.2
Systolic blood pressure (mmHg) 124  20 127  16
Hypertension (%) 36.1 40.0
Hypertension treatment (%) 26.4 26.3
Fasting plasma glucose (mg/dl) 98  17 105  24
Diabetes (%) 7.2 10.8
Metabolic syndrome (%) 38.3 41.9
Physical activity index 37.4 38.2
Smoking (%)
Current 41.5 39.3
Former 47.7 51.1
Never 10.8 14.9
Alcohol use (%)* 16.0 14.9
Postmenopausal (%) 81.6 —
Hormone replacement therapy (%) 36.9 —
CT fat measures (cm
3)
Visceral fat 1,627  869 2,539  1,045
Subcutaneous fat 3,350  1,378 2,676  1,124
Pericardial fat 109  40 135  51
Intrathoracic fat 85  43 146  63
Adiponectin (g/ml) 11.0 (7.6–16.5) 6.3 (4.2–9.0)
Resistin (ng/ml) 13.1 (10.5–16.3) 13.0 (10.3–17.0)
Data are means SD or median (25th–75th percentile). *Defined as7 drinks/week (for women) or14
drinks/week (for men). Conversion to SI units: multiply waist circumference by 2.54 for cm, triglycerides by
0.01129 for mmol/l, HDL and total cholesterol by 0.02586 for mmol/l, and fasting plasma glucose by
0.05551 for mmol/l.
Table 2—Age-adjusted Pearson correlation coefficients between fat depot volumes and adi-
pokines
Women Men
Adiponectin Log resistin Adiponectin Log resistin
n 501 501 415 415
Visceral fat 0.34* 0.16* 0.26* 0.08
Subcutaneous fat 0.21* 0.17* 0.02 0.13†
Pericardial fat 0.19* 0.16* 0.15† 0.11‡
Intrathoracic fat 0.21* 0.21* 0.22* 0.14†
*P  0.001; †P  0.01; ‡P  0.05.
Jain and Associates
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additional adjustment for adiponectin,
but strong associations were still ob-
served. After multivariable adjustment,
HDL cholesterol was 5.1  0.7 mg/dl
(0.13  0.02 mmol/l) lower per SD in-
crease of VAT. After further adjustment
for adiponectin, HDL cholesterol was
3.1  0.6 mg/dl (0.08  0.02 mmol/l)
lower per SD increase of VAT. Fasting
plasma glucose and diabetes did not ap-
preciably change after adjustment for adi-
ponectin. For SAT, similar results were
observed.
In men, there was more attenuation of
the effect size of VAT on fasting plasma
glucose, but not for diabetes, after addi-
tional adjustment for adiponectin. The ef-
fect size of VAT on HDL cholesterol was
minimally weakened after additional ad-
justment for adiponectin. Relations be-
tween VAT, log triglycerides, and metabolic
syndrome, as well as between SAT and
cardiometabolic risk factors, did not ap-
preciably change after adjustment for adi-
ponectin in men. None of the associations
between VAT, SAT, and cardiometabolic
risk factors appreciably changed upon ad-
justment for resistin (online appendix Ta-
bles 1A and 1B).
CONCLUSIONS— In the communi-
ty-based Framingham offspring cohort,
VAT, SAT, pericardial fat, and intratho-
racic fat were negatively correlated with
adiponectin but positively correlated with
resistin. For both sexes, the strongest cor-
relation was between VAT and adiponec-
tin, but the correlation coefficients were
still weak. Furthermore, the addition of
VAT only increased the model R2 for adi-
ponectin from 2–4% to 10–13%. VAT is
not a primary determinant of systemic to-
tal adiponectin concentration, and circu-
lating levels of adiponectin cannot be
used as a surrogate for VAT. Adjustment
for adiponectin attenuated relations be-
tween VAT, SAT, and cardiometabolic
risk factors, but adiponectin did not fully
account for the strong relations between
VAT and cardiometabolic risk factors.
Easily obtainable anthropometric mea-
sures (BMI and waist circumference) did
not explain the associations between VAT
and adiponectin in women or men and
between pericardial fat, intrathoracic fat,
and adiponectin in men. Therefore, ec-
topic fat depots may provide some addi-
tional insight about systemic adiponectin
concentrations not apparent with mea-
sures of general adiposity.
The modest inverse association be-
tween VAT and adiponectin has been ob-
served previously (6,8,11). We observed
strong sex interactions in the effect size of
VAT on systemic adiponectin concentra-
tion. Other studies have demonstrated
significant sex interactions in the associa-
tions between VAT and cardiometabolic
risk factors (1,7). VAT may have higher
lipolytic activity in women compared
with men (12). Sex differences in free fatty
acid delivery to the liver may account for
the observed sex interactions, but the
mechanisms are still not clear.
The associations between fat depots
and resistin have not been extensively
studied. The role of resistin in human
obesity is controversial, but a recent can-
didate gene study (13) suggests an asso-
ciation between resistin and regional fat
distribution and metabolic complications
in HIV lipodystrophy. We were able to
observe small but significant associations
between fat depots and resistin.
The strong relations between VAT,
diabetes, dyslipidemia, hypertension, and
metabolic syndrome have been observed
previously. The results of the present
study reveal that adiponectin does not
fully explain the relations between VAT,
systolic blood pressure, diabetes, and
metabolic syndrome. The associations be-
tween VAT, log triglycerides, HDL choles-
terol, and fasting plasma glucose were
attenuated, but not fully accounted for, by
adiponectin. These findings contrast with
prior work in the Health, Aging, and Body
Composition Cohort, where the associ-
ation between VAT and diabetes in a
multivariable model was minimally at-
tenuated by adjustment for combination
of adiponectin, leptin, and plasminogen
activator inhibitor-1 (11). However,
PAI-1 was the only adipokine found to be
independently associated with incident
diabetes. Given the modest correlations
between VAT, SAT, and adiponectin, it is
not surprising that we did not observe
more attenuation in these models. Adjust-
ment for resistin did not weaken any of
the associations between VAT and cardio-
metabolic risk factors.
The differential associations between
VAT, SAT, and adiponectin may be ex-
plained by differential adipocyte adipo-
kine production and regulatory feedback
of local inflammatory signals. Several
small studies in lean and obese nondia-
betic participants have shown that adi-
ponectin mRNA levels are lower in VAT
compared with SAT (14,15), although
these findings are not universal (16). VAT
is associated with several inflammatory
Table 3—Sex-specific multivariable-adjusted* regressions for fat depot volumes with adipokines
Women Men
P‡Effect size† R2 (%) P Effect size† R2 (%) P
Adiponectin§
Visceral fat 2.1 (1.5 to 2.7) 13 0.001 1.1 (0.7 to 1.5) 10 0.001 0.001
Subcutaneous fat 1.2 (0.6 to 1.8) 6 0.001 0.1 (0.3 to 0.5) 4 0.54 0.001
Pericardial fat 1.2 (0.6 to 1.8) 6 0.001 0.6 (0.2 to 1.0) 6 0.005 0.03
Intrathoracic fat 1.2 (0.6 to 1.8) 5 0.001 0.9 (0.5 to 1.3) 8 0.001 0.07
Log resistin
Visceral fat 1.06 (1.03–1.10) 6 0.001 1.04 (1.00–1.08) 3 0.07 0.15
Subcutaneous fat 1.06 (1.03–1.10) 6 0.001 1.05 (1.01–1.10) 4 0.008 0.88
Pericardial fat 1.04 (1.00–1.08) 5 0.03 1.05 (1.01–1.10) 4 0.01 0.77
Intrathoracic fat 1.06 (1.02–1.09) 6 0.002 1.07 (1.03–1.11) 5 0.002 0.43
*Adjusted for age, smoking, alcohol use, menopausal status (women only), and hormone replacement therapy (women only). †Effect size refers to the average change
in adiponectin or resistin concentration per SD of visceral, subcutaneous, pericardial, or intrathoracic fat volume. Effect sizes for log resistin were back transformed
to a nonlogarithmic scale. ‡P value for sex interaction obtained from multivariable regression analysis on entire sample, adjusted for sex, age, smoking, alcohol use,
menopausal status (women only), hormone replacement therapy (women only), and a sex-by-fat interaction term. §R2 of model with covariates only is 2% in women
and 4% in men. R2 of model with covariates only is 4% in women and 3% in men.
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markers, even after adjustment for BMI
and waist circumference (17). Tumor ne-
crosis factor-, interleukin-6, and C-reac-
tive protein can suppress adiponectin
gene expression. In addition, adiponectin
binds to complement factors and injured
vessel walls (18); therefore, adiponectin
concentrations may be further reduced in
the presence of a high VAT volume and
systemic inflammation. In humans, resis-
tin is primarily derived from macro-
phages that have infiltrated adipose tissue
(19). A rodent study (20) revealed that
macrophage content is higher in VAT
compared with SAT in db/db mice but had
similar concentrations in control mice.
Given the modest correlations be-
tween VAT and adiponectin, adiponectin
does not appear to be a good serum proxy
for VAT. Adjustment for adiponectin af-
fected relations between VAT and fasting
plasma glucose in men, HDL cholesterol,
and log triglycerides, albeit minimally.
These findings suggest that additional cir-
culating biomarkers and hormones may
mediate the relations between VAT and
cardiometabolic risk factors. It is also pos-
sible that high molecular weight adi-
ponectin, rather than total adiponectin,
may be a more potent mediator of the as-
sociations between VAT and cardiometa-
bolic risk factors.
The strengths of this study include a
well-characterized study sample and pre-
cise volumetric quantification of adipose
tissue. The limitations include the cross-
sectional design of the study, lack of eth-
nic diversity, noncontemporaneous CT
and adipokine concentrations, and adi-
ponectin assay. Given the cross-sectional,
observational nature of our study design,
causality cannot be inferred. Because the
sample is comprised of primarily white
participants, generalizability to other
ethnic groups is uncertain. Adipokine
concentrations, as well as glucose, choles-
terol, and anthropometric measurements,
were obtained several years before the
CTs were performed. Serum adiponectin
levels and cardiometabolic risk factors
may have changed at the time of the CTs,
and regional fat depot measurements may
have been different at the time of adipo-
kine concentrations. However, adipokine
measurements have been shown to be sta-
ble over a 1-year period (9). Nonetheless,
we cannot rule out misclassification based
on the 4-year time lag between the adipo-
kine and CT measurements that may have
affected our results. Any minor variation
in adipokine measurements should not
impact the relative association among
VAT, SAT, pericardial fat, intrathoracic
fat, and adipokines, which is the primary
focus of this study. We measured sys-
temic levels and not local adipokine con-
centrations, and systemic levels may not
reflect local production and release by all
regional fat depots. Adipokines produced
by VAT are released into portal circula-
tion, where hormones can be metabo-
lized. Therefore, systemic adiponectin
concentration may underestimate adi-
ponectin concentration that is actually se-
creted by VAT. However, a recent study
did not demonstrate a difference between
portal and systemic adiponectin concen-
trations (21); therefore, this is unlikely to
explain our results. Lastly, high molecular
weight adiponectin is more strongly asso-
ciated with regional adiposity and meta-
bolic diseases than total adiponectin (22).
Thus, our results may have been stronger
if we had measured high molecular
weight adiponectin instead of total adi-
ponectin. Adiponectin and resistin are
correlated with fat depots cross-
sectionally, but none of these adipokines
can serve as surrogates for these fat
depots. Relations among VAT, SAT, and
cardiometabolic risk factors were not
fully explained by adiponectin or resistin
concentrations.
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